Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06470607
Recruiting Observational

The Lymphocytic Infiltrate of Lung Tumors.

NCT06470607 · tracked via the Priya Life Science Italy tracker
Sponsor
Scientific Institute San Raffaele
Phase
Observational
Started
2023-01-20
Last updated
2024-11-29

Condition(s) studied

Lung CancerImmune System

Study summary

The study is configured as a monocentric observational transversal biological study.

The main objective of the study is the reconstruction of the molecular organization of tumors of the thoracic cavity, in particular non-small cell lung cancer (NSCLC).

The study involves the collection of clinical data and biological material (blood and tumor tissue) from 70 subjects diagnosed with thoracic tumors.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Ability to provide informed consent; * Men and women over the age of 18; * Patients candidates for surgical treatment diagnosed with thoracic tumors Exclusion Criteria: * Previous chemotherapy for any cancer within the last 6 months; * Pregnant and/or breastfeeding women; * Immunosuppressive state (states of immunosuppression or ongoing immunosuppressive/immunomodulatory treatments)

Primary outcome measure(s)

  • LYMPHOCYTE ISOLATION — from enrollment in the study to surgery at 15 days
    the collection of lymphocytes, and their sequencing and analysis of differentially expressed genes.

Trial sites (1)

FacilityCityRegionStatus
Scientific Institute Ospedale San Raffaele Milan Italy Recruiting

More Scientific Institute San Raffaele trials in Italy

Dynamics of Platelet Activation in Patients With Ventricular Assist Device (VAD) Recruiting
Role of Endomyocardial Biopsy and Aetiology-based Treatment in Pediatric Patients with Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management (MYOPED) Recruiting
Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers Recruiting
GEAM Study Aims At Assessing the Role of Genetic Testing in Patients with Arrhythmic Myocarditis. Recruiting
Prevention of Smoking Related Diseases Recruiting

Other trials for the same condition

Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia Recruiting
Ambispective Registry of Patients Affected by Lung Cancer Recruiting
AI for Lung Cancer Risk Definition in Computed Tomography Screening Programs Active, not recruiting
Plasma microRNA Profiling as First Line Screening Test for Lung Cancer Detection: a Prospective Study Active, not recruiting
Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06470607 on ClinicalTrials.gov ↗ ← All trials in Italy